Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S.
Capricor Therapeutics and Nippon Shinyaku (US subsidiary: NS Pharma) have announced that they have entered into an agreement for the exclusive commercialization and distribution in the United States of CAP-1002, Capricor’s novel cell therapy candidate…Learn More